Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo

PLoS Neglected Tropical Diseases

Volumn 9, Issue 3, 2015, Pages

  Adekunle, Adeshina I ^a   Pinkevych, Mykola ^a   McGready, Rose ^b,c   Luxemburger, Christine ^b   White, Lisa J ^c,d   Nosten, François ^b,c   Cromer, Deborah ^a   Davenport, Miles P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; PRIMAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ARTICLE; DRUG EFFICACY; ENDEMIC DISEASE; HUMAN; INFECTION RATE; INOCULATION; MICROBIAL POPULATION DYNAMICS; MICROSCOPY; NONHUMAN; PAPUA NEW GUINEA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIMARY INFECTION; SEASONAL VARIATION; THAILAND; VIRUS REACTIVATION; AGED; ANIMAL; BIOLOGICAL MODEL; FEMALE; LIVER; MALARIA, VIVAX; MALE; PARASITOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPOROZOITE; TORPOR;

AGED; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; FEMALE; HUMANS; LIVER; MALARIA, VIVAX; MALE; MODELS, BIOLOGICAL; PAPUA NEW GUINEA; PLASMODIUM VIVAX; PRIMAQUINE; SPOROZOITES; THAILAND; TORPOR;

EID: 84928803646     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003595     Document Type: Article

References (32)

1. Mendis K, Sina BJ, Marchesini P, Carter R, The neglected burden of Plasmodium vivax malaria. The American journal of tropical medicine and hygiene. 2001;64(1 suppl):97–106.
2. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS neglected tropical diseases. 2010;4(8):e774. doi: 10.1371/journal.pntd.0000774 20689816
3. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6(9):e1814. doi: 10.1371/journal.pntd.0001814 PubMed PMID: 22970336; PubMed Central PMCID: PMC3435256.
4. Miller LH, Good MF, Milon G, Malaria pathogenesis. Science. 1994;264(5167):1878–83. 8009217
5. Kitchen S, The infection of reticulocytes by Plasmodium vivax. The American Journal of Tropical Medicine and Hygiene. 1938;1(4):347–59.
6. Arnott A, Barry AE, Reeder JC, Understanding the population genetics of Plasmodium vivax is essential for malaria control and elimination. Malar J. 2012;11:14. doi: 10.1186/1475-2875-11-14 22233585
7. Baird JK, Real-world therapies and the problem of vivax malaria. New England Journal of Medicine. 2008;359(24):2601–3. doi: 10.1056/NEJMe0808729 19064622
8. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age. Journal of Infectious Diseases. 2012;206(11):1771–80. doi: 10.1093/infdis/jis580 22966124
9. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, et al. Treatment of vivax malaria on the western border of Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1999;93(4):433–8. 10674098
10. McCollum AM, Soberon V, Salas CJ, Santolalla ML, Udhayakumar V, Escalante AA, et al. Genetic variation and recurrent parasitaemia in Peruvian Plasmodium vivax populations. Malar J. 2014;13:67. doi: 10.1186/1475-2875-13-67 PubMed PMID: 24568141; PubMed Central PMCID: PMC3941685.
11. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, et al. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. Journal of Infectious Diseases. 2009;199(7):1074–80. doi: 10.1086/597303 19275476
12. Andrianaranjaka V, Lin JT, Golden C, Juliano JJ, Randrianarivelojosia M, Activation of minority-variant Plasmodium vivax hypnozoites following artesunate + amodiaquine treatment in a 23-year old man with relapsing malaria in Antananarivo, Madagascar. Malar J. 2013;12:177. doi: 10.1186/1475-2875-12-177 PubMed PMID: 23721298; PubMed Central PMCID: PMC3671981.
13. Chen N, Auliff A, Rieckmann K, Cheng Q, Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. Journal of Infectious Diseases. 2007;195(7):934–41. 17330782
14. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. Journal of Infectious Diseases. 2007;195(7):927–33. 17330781
15. Baird JK, Hoffman SL, Primaquine therapy for malaria. Clinical infectious diseases. 2004;39(9):1336–45. 15494911
16. Organization WH. Guidelines for the Treatment of Malaria: World Health Organization; 2010. doi: 10.1186/1475-2875-9-212 20649950
17. Koepfli C, Colborn KL, Kiniboro B, Lin E, Speed TP, Siba PM, et al. A high force of plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in papua new guinean children. PLoS Negl Trop Dis. 2013;7(9):e2403. doi: 10.1371/journal.pntd.0002403 PubMed PMID: 24040428; PubMed Central PMCID: PMC3764149.
18. Adak T, Sharma VP, Orlov VS, Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg. 1998;59(1):175–9. PubMed PMID: 9684649.
19. White NJ, Determinants of relapse periodicity in Plasmodium vivax malaria. Malaria journal. 2011;10(1):297.
20. Shute P, Lupascu G, Branzei P, Maryon M, Constantinescu P, Bruce-Chwatt L, et al. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1976;70(5–6):474–81. 841658
21. Bright AT, Manary MJ, Tewhey R, Arango EM, Wang T, Schork NJ, et al. A high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings. PLoS Negl Trop Dis. 2014;8(6):e2882. doi: 10.1371/journal.pntd.0002882 PubMed PMID: 24901334; PubMed Central PMCID: PMC4046966.
22. de Araujo FCF, de Rezende AM, Fontes CJF, Carvalho LH, de Brito CFA, Multiple-clone activation of hypnozoites is the leading cause of relapse in Plasmodium vivax infection. PloS one. 2012;7(11):e49871. doi: 10.1371/journal.pone.0049871 23185469
23. Imwong M, Boel ME, Pagornrat W, Pimanpanarak M, McGready R, Day NP, et al. The first Plasmodium vivax relapses of life are usually genetically homologous. Journal of Infectious Diseases. 2012;205(4):680–3. doi: 10.1093/infdis/jir806 22194628
24. Venkatesan P, Dedicoat M, Innes JA, Ellis CJ, Seasonality of presentation of imported Plasmodium vivax malaria in Birmingham, UK. Trans R Soc Trop Med Hyg. 2003;97(5):550. PubMed PMID: 15307423.
25. Koepfli C, Colborn KL, Kiniboro B, Lin E, Speed TP, Siba PM, et al. A high force of Plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in Papua New Guinean children. PLoS neglected tropical diseases. 2013;7(9):e2403. doi: 10.1371/journal.pntd.0002403 24040428
26. Xainli J, Baisor M, Kastens W, Bockarie M, Adams JH, King CL, Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. The Journal of Immunology. 2002;169(6):3200–7. 12218138
27. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011;52(5):612–20. doi: 10.1093/cid/ciq249 PubMed PMID: 21292666; PubMed Central PMCID: PMC3060895.
28. Mayxay M, Pukrittayakamee S, Newton PN, White NJ, Mixed-species malaria infections in humans. Trends in parasitology. 2004;20(5):233–40. doi: 10.1016/j.pt.2004.03.006 PubMed PMID: 15105024.
29. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. New England Journal of Medicine. 2013;369(14):1381–2. doi: 10.1056/NEJMc1301936 24088113
30. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J. 2012;11:259. doi: 10.1186/1475-2875-11-259 22856549
31. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S, CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics and genomics. 2007;17(2):93–101. 17301689
32. von Ahsen N, Tzvetkov M, Karunajeewa HA, Gomorrai S, Ura A, Brockmöller J, et al. CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. International journal of molecular epidemiology and genetics. 2010;1(4):310. 21532842